Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood blood.2024025154.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

Kai Huebel, MD, Alessandro Re, MD, Ariane Boumendil, PhD, Herve Finel, Marcus Hentrich, Mariagrazia Michieli, Edward Kanfer, Jose Luis Diez-Martin, MD PhD, Pascual Balsalobre, Laure Vincent, Wilfried Schroyens, MD PhD, Josep Maria Ribera Santasusana, Nicolaus Kröger, MD, Xaver Schiel, MD, Kirsty J Thomson, MD, Jorge Sierra, MD, Aida Botelho Sousa, Silvia Montoto, MD, Peter Dreger, MD

Blood (2016) 128 (22): 2257.

https://doi.org/10.1182/blood.V128.22.2257.2257

Published: 2016

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age

Blood (2016) 128 (22): 4691.

https://doi.org/10.1182/blood.V128.22.4691.4691

Published: 2016

Journal Articles

CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status

Rob S. Sellar, Frederick Arce Vargas, Jake Y. Henry, Stephanie Verfuerth, Sarah Charrot, Brendan Beaton, Ronjon Chakraverty, Sergio A. Quezada, Stephen Mackinnon, Kirsty J. Thomson, Karl S. Peggs

Blood (2015) 125 (4): 731–739.

https://doi.org/10.1182/blood-2014-07-589150

Published: 2015

Includes: Supplemental data

Journal Articles

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

Rob S Sellar, MBBS, Frederick Arce Vargas, PhD, Jake Henry, Simon Thomas, PhD, Alka Stansfield, Stephanie Verfuerth, PhD, Sarah C Charrot, MBBS, Rachael E Hough, MD, Sergio A Quezada, PhD, Kirsty J Thomson, MD, Stephen Mackinnon, MD, Karl S Peggs, MD

Blood (2013) 122 (21): 4524.

https://doi.org/10.1182/blood.V122.21.4524.4524

Published: 2013

Journal Articles

CMV-specific cellular therapy for acute myeloid leukemia?

Kirsty J. Thomson, Stephen Mackinnon, Karl S. Peggs

Blood (2012) 119 (4): 1088–1090.

https://doi.org/10.1182/blood-2011-10-383943

Published: 2012

Journal Articles

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Adam J. Mead, Kirsty J. Thomson, Emma C. Morris, Sajir Mohamedbhai, Shari Denovan, Guillermo Orti, Adele K. Fielding, Panagiotis D. Kottaridis, Rachael Hough, Ronjon Chakraverty, David C. Linch, Stephen Mackinnon, Karl S. Peggs

Blood (2010) 115 (25): 5147–5153.

https://doi.org/10.1182/blood-2010-01-265413

Published: 2010

Includes: Supplemental data

Journal Articles

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma

Jonathan R. Lambert, Jamshed B. Bomanji, Karl S. Peggs, Kirsty J. Thomson, Ronjon K. Chakraverty, Adele K. Fielding, Panagiotis D. Kottaridis, Michael Roughton, Emma C. Morris, Anthony H. Goldstone, David C. Linch, Peter J. Ell, Stephen Mackinnon

Blood (2010) 115 (14): 2763–2768.

https://doi.org/10.1182/blood-2009-11-255182

Published: 2010

Journal Articles

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Adam J Mead, Kirsty J Thomson, Emma C Morris, Ronjon Chakraverty, David C. Linch, FRCP, Stephen Mackinnon, MD, Karl S Peggs

Blood (2008) 112 (11): 3008.

https://doi.org/10.1182/blood.V112.11.3008.3008

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Emma C. Morris, MD, Asim Khwaja, MD, David C. Linch, MD, Anthony H. Goldstone, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 2053.

https://doi.org/10.1182/blood.V106.11.2053.2053

Published: 2005

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

CD34 + cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion

Kirsty J. Thomson, Stuart Ings, Michael Watts, Stephen Mackinnon, Karl S. Peggs

Blood (2004) 103 (2): 743.

https://doi.org/10.1182/blood-2003-08-2896

Published: 2004

Journal Articles

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Emma C. Morris, Peppy Rebello, Kirsty J. Thomson, Karl S. Peggs, Charalampia Kyriakou, Anthony H. Goldstone, Stephen Mackinnon, Geoff Hale

Blood (2003) 102 (1): 404–406.

https://doi.org/10.1182/blood-2002-09-2687

Published: 2003

NARROW

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age

CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

CMV-specific cellular therapy for acute myeloid leukemia?

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

CD34 + cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only